Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor

  • Eric D. Tetzlaff
  • Jaffer A. AjaniEmail author
Case Report


Carcinoid tumors are rare and often resistant to chemotherapy agents. Although a slow-growing tumor, patients can have significant morbidity associated with carcinoid syndrome and patients will often die as a result of tumor progression. We report the first case of a patient with a metastatic carcinoid tumor to respond to an oxaliplatin-based regimen. Further studies are needed to validate this observation.

Key Words

Carcinoid chromogranin A interferon alpha octreotide oxaliplatin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lubarsch O. Uber den primareren krebs des ileim nebst bemerkungen ueber das gleichzeitige vorkommen von krebs und tuberculos. Virchows Arch 1888;11:280–317.Google Scholar
  2. 2.
    Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of appendicular mucosa. Am J Pathol 1928;4:181–212.Google Scholar
  3. 3.
    Maggard MA, o’connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117–122.PubMedCrossRefGoogle Scholar
  4. 4.
    Schnirer I, Yao J, Ajani J. Carcinoid: a comprehensive review. Acta Oncol 2003;42(7):672–692.PubMedCrossRefGoogle Scholar
  5. 5.
    Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327–324.PubMedGoogle Scholar
  6. 6.
    Saltz L, Kemeny N, Schwartz G, et al. A phase II trial of alpha-interferon and 5-fluorouracil in patients with alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994;74:958–961.PubMedCrossRefGoogle Scholar
  7. 7.
    Pazdur R. Food and Drug Administration [FDA Website] January 9, 2004. Available at: Accessed July 22, 2005.Google Scholar
  8. 8.
    Kweekwl D, Gelderblom H, Guchelaar H. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90–105.CrossRefGoogle Scholar
  9. 9.
    Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colrectal carcinoma who were resistant to previous treatment with fluoropyramidnes. Annal Oncol 1996;7:95–98.Google Scholar
  10. 10.
    Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69(4):893–900.PubMedCrossRefGoogle Scholar
  11. 11.
    Chollet P, Bensmaine A, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Annal Oncol 1996;7:1065–1070.Google Scholar
  12. 12.
    Monnet I, Brienza S, Hugret F, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 1998;34:1124–1127.PubMedCrossRefGoogle Scholar
  13. 13.
    Louvet C, Andre T, Tiagaud JM. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543–4548.PubMedCrossRefGoogle Scholar
  14. 14.
    Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205–216.PubMedCrossRefGoogle Scholar
  15. 15.
    Andre T, Corrado B, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 1004;350:2343–2351.Google Scholar
  16. 16.
    de Gramont A, Figer A, Seymour M, et al. Lurcovorin and fluorouracil with or without oxaliplatin as first line treatment of metastatic colon cancer. J Clin Oncol 2000;18:2938–2947.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  1. 1.Department of Gastrointestinal Oncology and Digestive SystemsThe University of Texas M.D. Anderson Cancer CenterHouston

Personalised recommendations